In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Biodexa Pharmaceuticals PLC (BDRX) has initiated its first clinical site in the U.S. for a phase 3 trial of eRapa, an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback